CMV neutralizing antigen binding proteins
US11230591B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 18, 2017 |
| Grant date | Jan 25, 2022 |
| Priority date | — |
| Expiry date | Apr 18, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/54
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.